Toronto, Ontario–(Newsfile Corp. – March 15, 2021) – Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF)(“Mindset” or the “Company“) is pleased to announce that it has filed a sixth provisional patent application with the United States Patent and Trademark Office. This most recent patent application covers a comprehensive range of novel N,N-Dimethyltryptamine (“DMT“) and 5-methoxy-N,N-dimethyltryptamine (“5…


Previous articlePsychedelic Bulletin: Harvard Revisits Psychedelics; MindMed Attracts Strategic Investor; Psychedelics Companies Shed Cannabis Assets
Next articleBright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model